Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The role of the phosphatidylinositol-3 kinase signaling pathway in the development of acral melanoma has recently gained evidence. Phosphatase and tensin homologue (PTEN), one of the key molecules in the pathway, acts as a tumor suppressor through either an Akt-dependent or Akt-independent pathway. Akt accelerates degradation of p53. Objective: We assessed the expression of PTEN, phospho- Akt (p-Akt), and p53 by immunohistochemistry in benign acral nevi, acral dysplastic nevi, and acral melanomas in the radial growth phase and with a vertical growth component. Methods: Ten specimens in each group were included. Paraffin-embedded specimens were immunostained with antibodies for PTEN, p-Akt, and p53. We scored both the staining intensity and the proportion of positive cells. The final score was calculated by multiplying the intensity score by the proportion score. Results: All specimens of benign acral nevi except one showed some degree of PTEN-negative cells. The numbers of p-Akt and p53-positive cells were higher in acral dysplastic nevi and melanoma than in benign nevi. P-Akt scores were 1.7, 1.8, 2.6, and 4.4, and p53 scores were 2.0, 2.1, 3.8, and 4.1 in each group. PTEN and p-Akt scores in advanced acral melanoma were higher than in the other neoplasms. Conclusion: The expression of PTEN was decreased and the expression of p-Akt was increased in acral melanoma, especially in advanced cases. The PTEN-induced pathway appears to affect the late stage of melanomagenesis. Altered expression of p-Akt is thought to be due to secondary changes following the loss of PTEN.
Abstract
Background: The role of the phosphatidylinositol-3 kinase signaling pathway in the development of acral melanoma has recently gained evidence. Phosphatase and tensin homologue (PTEN), one of the key molecules in the pathway, acts as a tumor suppressor through either an Akt-dependent or Akt-independent pathway. Akt accelerates degradation of p53. Objective: We assessed the expression of PTEN, phospho- Akt (p-Akt), and p53 by immunohistochemistry in benign acral nevi, acral dysplastic nevi, and acral melanomas in the radial growth phase and with a vertical growth component. Methods: Ten specimens in each group were included. Paraffin-embedded specimens were immunostained with antibodies for PTEN, p-Akt, and p53. We scored both the staining intensity and the proportion of positive cells. The final score was calculated by multiplying the intensity score by the proportion score. Results: All specimens of benign acral nevi except one showed some degree of PTEN-negative cells. The numbers of p-Akt and p53-positive cells were higher in acral dysplastic nevi and melanoma than in benign nevi. P-Akt scores were 1.7, 1.8, 2.6, and 4.4, and p53 scores were 2.0, 2.1, 3.8, and 4.1 in each group. PTEN and p-Akt scores in advanced acral melanoma were higher than in the other neoplasms. Conclusion: The expression of PTEN was decreased and the expression of p-Akt was increased in acral melanoma, especially in advanced cases. The PTEN-induced pathway appears to affect the late stage of melanomagenesis. Altered expression of p-Akt is thought to be due to secondary changes following the loss of PTEN.
참고문헌 (27)
- Curtin JA., "Distinct sets of genetic alterations in melanoma", N Engl J Med, 353, pp.2135~2147 (2005)
- Broekaert SM., "Genetic and morphologic features for melanoma classification", Pigment Cell Melanoma Res, 23, pp.763~770 (2010)
- Blanco-Aparicio C., "PTEN, more than the AKT pathway", Carcinogenesis, 28, pp.1379~1386 (2007)
- Saraiva VS., "Immunohistochemical expression of phospho-Akt in uveal melanoma", Melanoma Res, 15, pp.245~250 (2005)
- Abraham AG., "PI3K", Akt-mediated regulation of p53 in cancer, 2014, pp.42, 798~803
- Annual report of cancer statistics in Korea, "Ministry of Health and Welfare", Ministry of Health and Welfare, ~ (2010)
- Kim SY., "Epidermal and adnexal nevi and tumors. In: Textbook of dermatology", pp.804~ (2014), Daehan Medical Publishing Co.
- Davies H., "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Goydos JS., "Detection of B-RAF and N-RAS mutations in human melanoma", J Am Coll Surg, 200, pp.362~370 (2005)
- Bastian BC., "Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin", Cancer Res, 60, pp.1968~1973 (2000)
- Zebary A., "KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma", J Dermatol Sci, 72, pp.284~289 (2013)
- Sansal I., "The biology and clinical relevance of the PTEN tumor suppressor pathway", J Clin Oncol, 22, pp.2954~2963 (2004)
- Freeman DJ., "PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms", Cancer Cell, 3, pp.117~130 (2003)
- Trotman LC., "PTEN and p53 : who will get the upper hand?", Cancer Cell, 3, pp.97~99 (2003)
- Reifenberger J., "Allelic losses on chromosome arm 10q and mutation of the PTEN(MMAC1)tumour suppressor gene in primary and metastatic malignant melanomas", Virchows Arch, 436, pp.487~493 (2000)
- Shull AY., "Novel somatic mutations to PI3K pathway genes in metastatic melanoma", PLoS One, 7, pp.e43369~ (2012)
- Whiteman DC., "Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma", Int J Cancer, 99, pp.63~67 (2002)
- Tsao H., "PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma", J Am Acad Dermatol, 49, pp.865~872 (2003)
- Davies MA., "A novel AKT3 mutation in melanoma tumours and cell lines", Br J Cancer, 99, pp.1265~1268 (2008)
- Dai DL., "Prognostic significance of activated Akt expression in melanoma : a clinicopathologic study of 292 cases", J Clin Oncol, 23, pp.1473~1482 (2005)
- Shanesmith RP., "Tissue microarray analysis of ezrin., KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions", Am J Dermatopathol, 33, pp.663~668 (2011)
- Ragnarsson-Olding BK., "Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes", Melanoma Res, 12, pp.453~463 (2002)
- Talve L., "Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin", Pathol Res Pract, 192, pp.825~833 (1996)
- McGregor JM., "p53 immunoreactivity in human malignant melanoma and dysplastic naevi", Br J Dermatol, 128, pp.606~611 (1993)
- Kanoko M., "Expression of p53 protein in melanoma progression", J Dermatol Sci, 12, pp.97~103 (1996)
- Niessner H., "Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases", Cancer Med, 2, pp.76~85 (2013)
- Mao M., "Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents", Clin Cancer Res, 19, pp.657~667 (2013)